Local delivery of small and large biomolecules in craniomaxillofacial bone

Advanced Drug Delivery Reviews

Volumn 64, Issue 12, 2012, Pages 1152-1164

  Ji, Wei ^a   Wang, Huanan ^a   van den Beucken, Jeroen J J P ^a   Yang, Fang ^a   Walboomers, X Frank ^a   Leeuwenburgh, Sander ^a   Jansen, John A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Animal model; Biomolecules; Bone regeneration; Craniomaxillofacial injuries; Drug delivery; Nanomedicine; Small molecule

Indexed keywords

ANIMAL MODEL; BONE DEFECT; BONE GRAFT; BONE REGENERATION; BONY DEFECTS; CLINICAL TREATMENTS; CRANIOMAXILLOFACIAL; LARGE BIOMOLECULES; LOCAL DELIVERY; PRE-CLINICAL; SMALL MOLECULES; STATE OF THE ART; SYNTHETIC BIOMATERIALS;

BIOLOGICAL MATERIALS; BIOMATERIALS; BIOMOLECULES; DEFECTS; DRUG DELIVERY; GRAFTS; MEDICAL NANOTECHNOLOGY;

BONE;

1 METHYL 2 PYRROLIDINONE; ALENDRONIC ACID; ALGINIC ACID; ANABOLIC AGENT; ANTIBIOTIC AGENT; ANTIESTROGEN; ANTINEOPLASTIC AGENT; BIOMATERIAL; BISPHOSPHONIC ACID DERIVATIVE; BONE CEMENT; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 9; CALCITONIN; CALCIUM PHOSPHATE CERAMIC; CHITOSAN; DOXYCYCLINE; ESTROGEN; GENTAMICIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NANOPARTICLE; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; POLYPEPTIDE ANTIBIOTIC AGENT; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA1; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; SYNTHETIC PEPTIDE; UNINDEXED DRUG; VASCULOTROPIN;

BONE CANCER; BONE INFECTION; BONE METASTASIS; BONE REGENERATION; CONTROLLED DRUG RELEASE; CRANIAL SINUS; CRANIOMAXILLOFACIAL BONE; CRANIOPLASTY; DESORPTION; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG MECHANISM; DRUG MEGADOSE; DRUG TARGETING; FRACTURE HEALING; HUMAN; HYDROGEL; JAW MALFORMATION; JAW OSTEONECROSIS; MOLECULAR SIZE; NONHUMAN; OSTEOMYELITIS; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; RNA INTERFERENCE; SKULL; SKULL DEFECT; STIMULUS RESPONSE; THROMBOCYTE RICH PLASMA; TOOTH MALFORMATION; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; BIOCOMPATIBLE MATERIALS; BONE DISEASES; BONE REGENERATION; BONE TRANSPLANTATION; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; FACIAL BONES; HUMANS;

EID: 84865305302     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2012.03.003     Document Type: Review

References (182)

1. Allareddy V., Allareddy V., Nalliah R.P. Epidemiology of facial fracture injuries. J. Oral Maxillofac. Surg. 2011, 69:2613-2618.
2. Disa J.J., Cordeiro P.G. Mandible reconstruction with microvascular surgery. Semin. Surg. Oncol. 2000, 19:226-234.
3. Emerick K.S., Teknos T.N. State-of-the-art mandible reconstruction using revascularized free-tissue transfer. Expert Rev. Anticancer Ther. 2007, 7:1781-1788.
4. Hallman M., Thor A. Bone substitutes and growth factors as an alternative/complement to autogenous bone for grafting in implant dentistry. Periodontol. 2000 2008, 2000(47):172-192.
5. Szpalski C., Barr J., Wetterau M., Saadeh P.B., Warren S.M. Cranial bone defects: current and future strategies. Neurosurg. Focus 2010, 29:E8.
6. Smith D.M., Cooper G.M., Mooney M.P., Marra K.G., Losee J.E. Bone morphogenetic protein 2 therapy for craniofacial surgery. J. Craniofac. Surg. 2008, 19:1244-1259.
7. Porter J.R., Ruckh T.T., Popat K.C. Bone tissue engineering: a review in bone biomimetics and drug delivery strategies. Biotechnol. Prog. 2009, 25:1539-1560.
8. Langer R., Vacanti J.P. Tissue engineering. Science 1993, 260:920-926.
9. Martins A., Duarte A.R.C., Faria S., Marques A.P., Reis R.L., Neves N.M. Osteogenic induction of hBMSCs by electrospun scaffolds with dexamethasone release functionality. Biomaterials 2010, 31:5875-5885.
10. Wang F., Li Z.Q., Khan M., Tamama K., Kuppusamy P., Wagner W.R., Sen C.K., Guan J.J. Injectable, rapid gelling and highly flexible hydrogel composites as growth factor and cell carriers. Acta Biomater. 2010, 6:1978-1991.
11. Murphy W.L., Peters M.C., Kohn D.H., Mooney D.J. Sustained release of vascular endothelial growth factor from mineralized poly(lactide-co-glycolide) scaffolds for tissue engineering. Biomaterials 2000, 21:2521-2527.
12. Moioli E.K., Clark P.A., Xin X., Lal S., Mao J.J. Matrices and scaffolds for drug delivery in dental, oral and craniofacial tissue engineering. Adv. Drug Deliv. Rev. 2007, 59:308-324.
13. Ji W., Sun Y., Yang F., van den Beucken J., Fan M.W., Chen Z., Jansen J.A. Bioactive electrospun scaffolds delivering growth factors and genes for tissue engineering applications. Pharm. Res. 2011, 28:1259-1272.
14. Kitaori T., Ito H., Schwarz E.M., Tsutsumi R., Yoshitomi H., Oishi S., Nakano M., Fujii N., Nagasawa T., Nakamura T. Stromal cell-derived factor 1/CXCR4 signaling is critical for the recruitment of mesenchymal stem cells to the fracture site during skeletal repair in a mouse model. Arthritis Rheum. 2009, 60:813-823.
15. Giannoudis P., Psarakis S., Kontakis G. Can we accelerate fracture healing? A critical analysis of the literature. Injury 2007, 38(Suppl. 1):S81-S89.
16. Lee S.H., Shin H. Matrices and scaffolds for delivery of bioactive molecules in bone and cartilage tissue engineering. Adv. Drug Deliv. Rev. 2007, 59:339-359.
17. Putney S.D., Burke P.A. Improving protein therapeutics with sustained-release formulations. Nat. Biotechnol. 1998, 16:153-157.
18. Olsen B.R., Reginato A.M., Wang W. Bone development. Annu. Rev. Cell Dev. Biol. 2000, 16:191-220.
19. Yang Y. Skeletal morphogenesis during embryonic development. Crit. Rev. Eukaryot. Gene Expr. 2009, 19:197-218.
20. Opperman L.A. Cranial sutures as intramembranous bone growth sites. Dev. Dyn. 2000, 219:472-485.
21. Mackie E.J., Ahmed Y.A., Tatarczuch L., Chen K.S., Mirams M. Endochondral ossification: how cartilage is converted into bone in the developing skeleton. Int. J. Biochem. Cell Biol. 2008, 40:46-62.
22. Gawlitta D., Farrell E., Malda J., Creemers L.B., Alblas J., Dhert W.J. Modulating endochondral ossification of multipotent stromal cells for bone regeneration. Tissue Eng. Part B Rev. 2010, 16:385-395.
23. Gorr S.U., Abdolhosseini M. Antimicrobial peptides and periodontal disease. J. Clin. Periodontol. 2011, 38(Suppl. 11):126-141.
24. Carek P.J., Dickerson L.M., Sack J.L. Diagnosis and management of osteomyelitis. Am. Fam. Physician 2001, 63:2413-2420.
25. Wald E.R. Risk factors for osteomyelitis. Am. J. Med. 1985, 78:206-212.
26. Eichhorn W., Wehrmann M., Blessmann M., Pohlenz P., Blake F., Schmelzle R., Heiland M. Metastases in odontogenic cysts: literature review and case presentation. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 2010, 109:582-586.
27. Tsiridis E., Upadhyay N., Giannoudis P. Molecular aspects of fracture healing: which are the important molecules?. Injury 2007, 38(Suppl. 1):S11-S25.
28. Feghali C.A., Wright T.M. Cytokines in acute and chronic inflammation. Front. Biosci. 1997, 2:d12-d26.
29. Brodbeck W.G., Voskerician G., Ziats N.P., Nakayama Y., Matsuda T., Anderson J.M. In vivo leukocyte cytokine mRNA responses to biomaterials are dependent on surface chemistry. J. Biomed. Mater. Res. A 2003, 64:320-329.
30. Dinarello C.A. Proinflammatory cytokines. Chest 2000, 118:503-508.
31. Peled A., Petit I., Kollet O., Magid M., Ponomaryov T., Byk T., Nagler A., Ben-Hur H., Many A., Shultz L., Lider O., Alon R., Zipori D., Lapidot T. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science 1999, 283:845-848.
32. Sordi V., Malosio M.L., Marchesi F., Mercalli A., Melzi R., Giordano T., Belmonte N., Ferrari G., Leone B.E., Bertuzzi F., Zerbini G., Allavena P., Bonifacio E., Piemonti L. Bone marrow mesenchymal stem cells express a restricted set of functionally active chemokine receptors capable of promoting migration to pancreatic islets. Blood 2005, 106:419-427.
33. Higashino K., Viggeswarapu M., Bargouti M., Liu H., Titus L., Boden S.D. Stromal cell-derived factor-1 potentiates bone morphogenetic protein-2 induced bone formation. Tissue Eng. Part A 2010, 17:523-530.
34. Gerstenfeld L.C., Cho T.J., Kon T., Aizawa T., Tsay A., Fitch J., Barnes G.L., Graves D.T., Einhorn T.A. Impaired fracture healing in the absence of TNF-alpha signaling: the role of TNF-alpha in endochondral cartilage resorption. J. Bone Miner. Res. 2003, 18:1584-1592.
35. Nie X., Luukko K., Kettunen P. BMP signalling in craniofacial development. Int. J. Dev. Biol. 2006, 50:511-521.
36. Hatch N.E. FGF signaling in craniofacial biological control and pathological craniofacial development. Crit. Rev. Eukaryot. Gene Expr. 2010, 20:295-311.
37. Cohen M.M. Hedgehog signaling update. Am. J. Med. Genet. A 2010, 152A:1875-1914.
38. Agholme F., Aspenberg P. Wnt signaling and orthopedics, an overview. Acta Orthop. 2011, 82:125-130.
39. Wozney J.M. Bone morphogenetic proteins. Prog. Growth Factor Res. 1989, 1:267-280.
40. Ripamonti U., Herbst N.N., Ramoshebi L.N. Bone morphogenetic proteins in craniofacial and periodontal tissue engineering: experimental studies in the non-human primate Papio ursinus. Cytokine Growth Factor Rev. 2005, 16:357-368.
41. Heliotis M., Ripamonti U., Ferretti C., Kerawala C., Mantalaris A., Tsiridis E. The basic science of bone induction. Br. J. Oral Maxillofac. Surg. 2009, 47:511-514.
42. Itoh N., Ornitz D.M. Evolution of the Fgf and Fgfr gene families. Trends Genet. 2004, 20:563-569.
43. Nie X., Luukko K., Kettunen P. FGF signalling in craniofacial development and developmental disorders. Oral Dis. 2006, 12:102-111.
44. Willert K., Brown J.D., Danenberg E., Duncan A.W., Weissman I.L., Reya T., Yates J.R., Nusse R. Wnt proteins are lipid-modified and can act as stem cell growth factors. Nature 2003, 423:448-452.
45. Young D.L., Schneider R.A., Hu D., Helms J.A. Genetic and teratogenic approaches to craniofacial development. Crit. Rev. Oral Biol. Med. 2000, 11:304-317.
46. Alsberg E., Hill E.E., Mooney D.J. Craniofacial tissue engineering. Crit. Rev. Oral Biol. Med. 2001, 12:64-75.
47. Gerstenfeld L.C., Cullinane D.M., Barnes G.L., Graves D.T., Einhorn T.A. Fracture healing as a post-natal developmental process: molecular, spatial, and temporal aspects of its regulation. J. Cell. Biochem. 2003, 88:873-884.
48. Keramaris N.C., Calori G.M., Nikolaou V.S., Schemitsch E.H., Giannoudis P.V. Fracture vascularity and bone healing: a systematic review of the role of VEGF. Injury 2008, 39(Suppl. 2):S45-S57.
49. Vaibhav B., Nilesh P., Vikram S., Anshul C. Bone morphogenic protein and its application in trauma cases: a current concept update. Injury 2007, 38:1227-1235.
50. Lehmann W., Edgar C.M., Wang K., Cho T.J., Barnes G.L., Kakar S., Graves D.T., Rueger J.M., Gerstenfeld L.C., Einhorn T.A. Tumor necrosis factor alpha (TNF-alpha) coordinately regulates the expression of specific matrix metalloproteinases (MMPS) and angiogenic factors during fracture healing. Bone 2005, 36:300-310.
51. Suzuki Y., Tanihara M., Suzuki K., Saitou A., Sufan W., Nishimura Y. Alginate hydrogel linked with synthetic oligopeptide derived from BMP-2 allows ectopic osteoinduction in vivo. J. Biomed. Mater. Res. 2000, 50:405-409.
52. Saito A., Suzuki Y., Ogata S., Ohtsuki C., Tanihara M. Accelerated bone repair with the use of a synthetic BMP-2-derived peptide and bone-marrow stromal cells. J. Biomed. Mater. Res. A 2005, 72:77-82.
53. Chen Y., Webster T.J. Increased osteoblast functions in the presence of BMP-7 short peptides for nanostructured biomaterial applications. J. Biomed. Mater. Res. A 2009, 91:296-304.
54. Bergeron E., Leblanc E., Drevelle O., Giguere R., Beauvais S., Grenier G., Faucheux N. The evaluation of ectopic bone formation induced by delivery systems for bone morphogenetic protein-9 or its derived peptide. Tissue Eng. Part A 2012, 18:345-352.
55. Rao N., Ziran B.H., Lipsky B.A. Treating osteomyelitis: antibiotics and surgery. Plast. Reconstr. Surg. 2011, 127(Suppl. 1):177S-187S.
56. Heitz-Mayfield L.J. Systemic antibiotics in periodontal therapy. Aust. Dent. J. 2009, 54(Suppl. 1):S96-S101.
57. Bidault P., Chandad F., Grenier D. Risk of bacterial resistance associated with systemic antibiotic therapy in periodontology. J. Can. Dent. Assoc. 2007, 73:721-725.
58. Guarneri V., Conte P.F. The curability of breast cancer and the treatment of advanced disease. Eur. J. Nucl. Med. Mol. Imaging 2004, 31(Suppl. 1):S149-S161.
59. Li Y.L., Quarles L.D., Zhou H.H., Xiao Z.S. RNA interference and its application in bone-related diseases. Biochem. Biophys. Res. Commun. 2007, 361:817-821.
60. Aigner A. Applications of RNA interference: current state and prospects for siRNA-based strategies in vivo. Appl. Microbiol. Biotechnol. 2007, 76:9-21.
61. Hicklin D.J., Ellis L.M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol. 2005, 23:1011-1027.
62. Liu T., Ye L., Chen X., Peng J., Zhang X., Yi H., Peng F., He Y., Leng A. Combination gene therapy using VEGF-shRNA and fusion suicide gene yCDglyTK inhibits gastric carcinoma growth. Exp. Mol. Pathol. 2011, 91:745-752.
63. Payne J.B., Golub L.M. Using tetracyclines to treat osteoporotic/osteopenic bone loss: from the basic science laboratory to the clinic. Pharmacol. Res. 2011, 63:121-129.
64. Ghayor C., Correro R.M., Lange K., Karfeld-Sulzer L.S., Gratz K.W., Weber F.E. Inhibition of osteoclast differentiation and bone resorption by N-methylpyrrolidone. J. Biol. Chem. 2011, 286:24458-24466.
65. Alexander I.M. Pharmacotherapeutic management of osteoprosis and osteopenia. Nurse Pract. 2009, 34:30-40. quiz 41.
66. Horiuchi N., Maeda T. Statins and bone metabolism. Oral Dis. 2006, 12:85-101.
67. Mundy G., Garrett R., Harris S., Chan J., Chen D., Rossini G., Boyce B., Zhao M., Gutierrez G. Stimulation of bone formation in vitro and in rodents by statins. Science 1999, 286:1946-1949.
68. Mundy G.R. Statins and their potential for osteoporosis. Bone 2001, 29:495-497.
69. Sugiyama M., Kodama T., Konishi K., Abe K., Asami S., Oikawa S. Compactin and simvastatin, but not pravastatin, induce bone morphogenetic protein-2 in human osteosarcoma cells. Biochem. Biophys. Res. Commun. 2000, 271:688-692.
70. Luginbuehl V., Meinel L., Merkle H.P., Gander B. Localized delivery of growth factors for bone repair. Eur. J. Pharm. Biopharm. 2004, 58:197-208.
71. Könnings S., Göpferich A. Lipospheres as delivery systems for peptides and proteins. Lipospheres in drug targets and delivery: approaches, methods, and applications 2005, 67-86. CRC Press LLC. C. Nastruzzi (Ed.).
72. Roy K., Wang D., Hedley M.L., Barman S.P. Gene delivery with in-situ crosslinking polymer networks generates long-term systemic protein expression. Mol. Ther. 2003, 7:401-408.
73. Storrie H., Mooney D.J. Sustained delivery of plasmid DNA from polymeric scaffolds for tissue engineering. Adv. Drug Deliv. Rev. 2006, 58:500-514.
74. Thomas C.E., Ehrhardt A., Kay M.A. Progress and problems with the use of viral vectors for gene therapy. Nat. Rev. Genet. 2003, 4:346-358.
75. Dinbergs I.D., Brown L., Edelman E.R. Cellular response to transforming growth factor-beta1 and basic fibroblast growth factor depends on release kinetics and extracellular matrix interactions. J. Biol. Chem. 1996, 271:29822-29829.
76. Seeherman H., Wozney J.M. Delivery of bone morphogenetic proteins for orthopedic tissue regeneration. Cytokine Growth Factor Rev. 2005, 16:329-345.
77. Huang X., Brazel C.S. On the importance and mechanisms of burst release in matrix-controlled drug delivery systems. J. Control. Release 2001, 73:121-136.
78. Grassi M., Grassi G. Mathematical modelling and controlled drug delivery: matrix systems. Curr. Drug Deliv. 2005, 2:97-116.
79. Gautschi O.P., Frey S.P., Zellweger R. Bone morphogenetic proteins in clinical applications. ANZ J. Surg. 2007, 77:626-631.
80. Giannoudis P.V., Kanakaris N.K., Einhorn T.A. Interaction of bone morphogenetic proteins with cells of the osteoclast lineage: review of the existing evidence. Osteoporos. Int. 2007, 18:1565-1581.
81. Nie H., Ho M.L., Wang C.K., Wang C.H., Fu Y.C. BMP-2 plasmid loaded PLGA/HAp composite scaffolds for treatment of bone defects in nude mice. Biomaterials 2009, 30:892-901.
82. Nie H., Wang C. Fabrication and characterization of PLGA/HAp scaffolds for delivery of BMP-2 plasmid composite DNA. J. Control. Release 2007, 120:111-121.
83. Chen Z.G. Small-molecule delivery by nanoparticles for anticancer therapy. Trends Mol. Med. 2010, 16:594-602.
84. Haidar Z., Hamdy R., Tabrizian M. Delivery of recombinant bone morphogenetic proteins for bone regeneration and repair. Part A: current challenges in BMP delivery. Biotechnol. Lett. 2009, 31:1817-1824.
85. Tayalia P., Mooney D.J. Controlled growth factor delivery for tissue engineering. Adv. Mater. 2009, 21:3269-3285.
86. Luginbuehl V., Meinel L., Merkle H.P., Gander B. Localized delivery of growth factors for bone repair. Eur. J. Pharm. Biopharm. 2004, 58:197-208.
87. Chen F.-M., Zhang M., Wu Z.-F. Toward delivery of multiple growth factors in tissue engineering. Biomaterials 2010, 31:6279-6308.
88. Mahmoudi M., Lynch I., Ejtehadi M.R., Monopoli M.P., Bombelli F.B., Laurent S. Protein-nanoparticle interactions: opportunities and challenges. Chem. Rev. 2011, null-null.
89. Anglin E.J., Cheng L., Freeman W.R., Sailor M.J. Porous silicon in drug delivery devices and materials. Adv Drug Deliv. Rev 2008, 60:1266-1277.
90. Sharon J.L., Puleo D.A. Immobilization of glycoproteins, such as VEGF, on biodegradable substrates. Acta Biomater. 2008, 4:1016-1023.
91. Lin C.-C., Metters A.T. Hydrogels in controlled release formulations: network design and mathematical modeling. Adv Drug Deliv. Rev 2006, 58:1379-1408.
92. Degat M.-C., Dahri-Correia L., Lavigne F., Meunier A., Sedel L., Correia J., Petite H., Logeart-Avramoglou D. Benzylaminated dextran-modified hydrogels: a long-term bioactive TGF-β1 carrier. J. Biomed. Mater. Res. A 2009, 91A:1178-1188.
93. Biondi M., Ungaro F., Quaglia F., Netti P.A. Controlled drug delivery in tissue engineering. Adv Drug Deliv. Rev 2008, 60:229-242.
94. Masters K.S. Covalent growth factor immobilization strategies for tissue repair and regeneration. Macromol. Biosci. 2011, n/a-n/a.
95. Chiu L.L.Y., Radisic M. Scaffolds with covalently immobilized VEGF and angiopoietin-1 for vascularization of engineered tissues. Biomaterials 2010, 31:226-241.
96. De Geest B.G., De Koker S., Demeester J., De Smedt S.C., Hennink W.E. Pulsed in vitro release and in vivo behavior of exploding microcapsules. J. Control. Release 2009, 135:268-273.
97. De Geest B.G., De Koker S., Immesoete K., Demeester J., De Smedt S.C., Hennink W.E. Self-exploding beads releasing microcarriers. Adv. Mater. 2008, 20:3687-3691.
98. Mouriño V., Boccaccini A.R. Bone tissue engineering therapeutics: controlled drug delivery in three-dimensional scaffolds. J. R. Soc. Interface 2010, 7:209-227.
99. Tabata Y. The importance of drug delivery systems in tissue engineering. Pharm. Sci. Technol. Today 2000, 3:80-89.
100. Freiberg S., Zhu X.X. Polymer microspheres for controlled drug release. Int. J. Pharm. 2004, 282:1-18.
101. Yang L., Webster T.J. Nanotechnology controlled drug delivery for treating bone diseases. Expert Opin. Drug Deliv. 2009, 6:851-864.
102. Tabata Y. Tissue regeneration based on growth factor release. Tissue Eng. 2003, 9:5-15.
103. Habraken W.J.E.M., Wolke J.G.C., Mikos A.G., Jansen J.A. PLGA microsphere/calcium phosphate cement composites for tissue engineering: in vitro release and degradation characteristics. J. Biomater. Sci. Polym. Ed. 2008, 19:1171-1188.
104. Eley J.G., Mathew P. Preparation and release characteristics of insulin and insulin-like growth factor-one from polymer nanoparticles. J. Microencapsul. 2007, 24:225-234.
105. Kumari A., Yadav S.K., Yadav S.C. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf., B 2010, 75:1-18.
106. Silva G.A., Coutinho O.P., Ducheyne P., Reis R.L. Materials in particulate form for tissue engineering. 2. Applications in bone. J. Tissue Eng. Regen. Med. 2007, 1:97-109.
107. Zhu G., Mallery S.R., Schwendeman S.P. Stabilization of proteins encapsulated in injectable poly (lactide-co-glycolide). Nat. Biotechnol. 2000, 18:52-57.
108. Ungaro F., Biondi M., d'Angelo I., Indolfi L., Quaglia F., Netti P.A., La Rotonda M.I. Microsphere-integrated collagen scaffolds for tissue engineering: effect of microsphere formulation and scaffold properties on protein release kinetics. J. Control. Release 2006, 113:128-136.
109. Wang X., Wenk E., Zhang X., Meinel L., Vunjak-Novakovic G., Kaplan D.L. Growth factor gradients via microsphere delivery in biopolymer scaffolds for osteochondral tissue engineering. J. Control. Release 2009, 134:81-90.
110. Needleman I., Tucker R., Giedrys-Leeper E., Worthington H. A systematic review of guided tissue regeneration for periodontal infrabony defects. J. Periodontal Res. 2002, 37:380-388.
111. Retzepi M., Donos N. Guided bone regeneration: biological principle and therapeutic applications. Clin. Oral Implants Res. 2010, 21:567-576.
112. Nie H., Wang C.-H. Fabrication and characterization of PLGA/HAp composite scaffolds for delivery of BMP-2 plasmid DNA. J. Control. Release 2007, 120:111-121.
113. Slaughter B.V., Khurshid S.S., Fisher O.Z., Khademhosseini A., Peppas N.A. Hydrogels in regenerative medicine. Adv. Mater. 2009, 21:3307-3329.
114. Yamamoto M., Ikada Y., Tabata Y. Controlled release of growth factors based on biodegradation of gelatin hydrogel. J. Biomater. Sci. Polym. Ed. 2001, 12:77-88.
115. Kretlow J.D., Young S., Klouda L., Wong M., Mikos A.G. Injectable biomaterials for regenerating complex craniofacial tissues. Adv. Mater. 2009, 21:3368-3393.
116. Quick D.J., Anseth K.S. DNA delivery from photocrosslinked PEG hydrogels: encapsulation efficiency, release profiles, and DNA quality. J. Control. Release 2004, 96:341-351.
117. Wang C., Varshney R.R., Wang D.-A. Therapeutic cell delivery and fate control in hydrogels and hydrogel hybrids. Adv. Drug Deliv. Rev. 2010, 62:699-710.
118. Bergeron E., Marquis M., Chrétien I., Faucheux N. Differentiation of preosteoblasts using a delivery system with BMPs and bioactive glass microspheres. J. Mater. Sci. Mater. Med. 2007, 18:255-263.
119. Uskoković V., Uskoković D.P. Nanosized hydroxyapatite and other calcium phosphates: chemistry of formation and application as drug and gene delivery agents. J. Biomed. Mater. Res. B 2011, 96B:152-191.
120. Habraken W.J.E.M., Wolke J.G.C., Jansen J.A. Ceramic composites as matrices and scaffolds for drug delivery in tissue engineering. Adv. Drug Deliv. Rev. 2007, 59:234-248.
121. Bisht S., Bhakta G., Mitra S., Maitra A. pDNA loaded calcium phosphate nanoparticles: highly efficient non-viral vector for gene delivery. Int. J. Pharm. 2005, 288:157-168.
122. Epple M., Ganesan K., Heumann R., Klesing J., Kovtun A., Neumann S., Sokolova V. Application of calcium phosphate nanoparticles in biomedicine. J. Mater. Chem. 2010, 20:18-23.
123. Habraken W.J.E.M., Wolke J.G.C., Mikos A.G., Jansen J.A. Injectable PLGA microsphere/calcium phosphate cements: physical properties and degradation characteristics. J. Biomater. Sci. Polym. Ed. 2006, 17:1057-1074.
124. Habraken W.J.E.M., Jonge L.T.d., Wolke J.G.C., Yubao L., Mikos A.G., Jansen J.A. Introduction of gelatin microspheres into an injectable calcium phosphate cement. J. Biomed. Mater. Res. A 2008, 87A:643-655.
125. Li M., Liu X., Liu X., Ge B., Chen K. Creation of macroporous calcium phosphate cements as bone substitutes by using genipin-crosslinked gelatin microspheres. J. Mater. Sci. Mater. Med. 2009, 20:925-934.
126. Muschler G.F., Raut V.P., Patterson T.E., Wenke J.C., Hollinger J.O. The design and use of animal models for translational research in bone tissue engineering and regenerative medicine. Tissue Eng. Part B Rev. 2010, 16:123-145.
127. Gomes P.S., Fernandes M.H. Rodent models in bone-related research: the relevance of calvarial defects in the assessment of bone regeneration strategies. Lab. Anim. 2011, 45:14-24.
128. Horner E.A., Kirkham J., Wood D., Curran S., Smith M., Thomson B., Yang X.B. Long bone defect models for tissue engineering applications: criteria for choice. Tissue Eng. Part B Rev. 2010, 16:263-271.
129. Oortgiesen D.A.W., Meijer G.J., de Vries R.B.M., Walboomers X.F., Jansen J.A. Animal models for the evaluation of tissue engineering constructs. Tissue Engineering; From Lab to Clinic 2011, 131-154. Springer-Verlag, Berlin. N. Pallua, C.V. Suschek (Eds.).
130. Cooper G.M., Mooney M.P., Gosain A.K., Campbell P.G., Losee J.E., Huard J. Testing the critical size in calvarial bone defects: revisiting the concept of a critical-size defect. Plast. Reconstr. Surg. 2010, 125:1685-1692.
131. Schmitz J.P., Hollinger J.O. The critical size defect as an experimental model for craniomandibulofacial nonunions. Clin. Orthop. Relat. Res. 1986, 299-308.
132. Develioglu H., Saraydin S.U., Bolayir G., Dupoirieux L. Assessment of the effect of a biphasic ceramic on bone response in a rat calvarial defect model. J. Biomed. Mater. Res. A 2006, 77:627-631.
133. Kim K.H., Jeong L., Park H.N., Shin S.Y., Park W.H., Lee S.C., Kim T.I., Park Y.J., Seol Y.J., Lee Y.M., Ku Y., Rhyu I.C., Han S.B., Chung C.P. Biological efficacy of silk fibroin nanofiber membranes for guided bone regeneration. J. Biotechnol. 2005, 120:327-339.
134. Blom E.J., Klein-Nulend J., Yin L., van Waas M.A., Burger E.H. Transforming growth factor-beta1 incorporated in calcium phosphate cement stimulates osteotransductivity in rat calvarial bone defects. Clin. Oral Implants Res. 2001, 12:609-616.
135. Woo B.H., Fink B.F., Page R., Schrier J.A., Jo Y.W., Jiang G., DeLuca M., Vasconez H.C., DeLuca P.P. Enhancement of bone growth by sustained delivery of recombinant human bone morphogenetic protein-2 in a polymeric matrix. Pharm. Res. 2001, 18:1747-1753.
136. King G.N. The importance of drug delivery to optimize the effects of bone morphogenetic proteins during periodontal regeneration. Curr. Pharm. Biotechnol. 2001, 2:131-142.
137. Nemcovsky C.E., Zahavi S., Moses O., Kebudi E., Artzi Z., Beny L., Weinreb M. Effect of enamel matrix protein derivative on healing of surgical supra-infrabony periodontal defects in the rat molar: a histomorphometric study. J. Periodontol. 2006, 77:996-1002.
138. Oortgiesen D.A., Meijer G.J., Bronckers A.L., Walboomers X.F., Jansen J.A. Fenestration defects in the rabbit jaw: an inadequate model for studying periodontal regeneration. Tissue Eng. Part C Methods 2010, 16:133-140.
139. Dogan A., Ozdemir A., Kubar A., Oygur T. Assessment of periodontal healing by seeding of fibroblast-like cells derived from regenerated periodontal ligament in artificial furcation defects in a dog: a pilot study. Tissue Eng. 2002, 8:273-282.
140. Salata L.A., Craig G.T., Brook I.M. Bone healing following the use of hydroxyapatite or ionomeric bone substitutes alone or combined with a guided bone regeneration technique: an animal study. Int. J. Oral Maxillofac. Implants 1998, 13:44-51.
141. Fennis J.P., Stoelinga P.J., Jansen J.A. Mandibular reconstruction: a clinical and radiographic animal study on the use of autogenous scaffolds and platelet-rich plasma. Int. J. Oral Maxillofac. Surg. 2002, 31:281-286.
142. Sun X.J., Xia L.G., Chou L.L., Zhong W., Zhang X.L., Wang S.Y., Zhao J., Jiang X.Q., Zhang Z.Y. Maxillary sinus floor elevation using a tissue engineered bone complex with BMP-2 gene modified bMSCs and a novel porous ceramic scaffold in rabbits. Arch. Oral Biol. 2010, 55:195-202.
143. Nevins M., Kirker-Head C., Nevins M., Wozney J.A., Palmer R., Graham D. Bone formation in the goat maxillary sinus induced by absorbable collagen sponge implants impregnated with recombinant human bone morphogenetic protein-2. Int. J. Periodontics Restorative Dent. 1996, 16:8-19.
144. Lopez-Nino J., Caballero L.G., Gonzalez-Mosquera A., Seoane-Romero J., Varela-Centelles P., Seoane J. Lamb ex-vivo model for training in maxillary sinus floor elevation surgery: a comparative study with human standards. J. Periodontol. 2012, 83:354-361.
145. Stelzle F., Benner K.U. An animal model for sinus floor elevation with great elevation heights. Macroscopic, microscopic, radiological and micro-CT analysis: ex vivo. Clin. Oral Implants Res. 2010, 21:1370-1378.
146. Kaufman E. Maxillary sinus elevation surgery: an overview. J. Esthet. Restor. Dent. 2003, 15:272-282. discussion 283.
147. Wikesjo U.M., Qahash M., Polimeni G., Susin C., Shanaman R.H., Rohrer M.D., Wozney J.M., Hall J. Alveolar ridge augmentation using implants coated with recombinant human bone morphogenetic protein-2: histologic observations. J. Clin. Periodontol. 2008, 35:1001-1010.
148. Bodde E.W., Boerman O.C., Russel F.G., Mikos A.G., Spauwen P.H., Jansen J.A. The kinetic and biological activity of different loaded rhBMP-2 calcium phosphate cement implants in rats. J. Biomed. Mater. Res. A 2008, 87:780-791.
149. Chen F.M., Zhao Y.M., Zhang R., Jin T., Sun H.H., Wu Z.F., Jin Y. Periodontal regeneration using novel glycidyl methacrylated dextran (Dex-GMA)/gelatin scaffolds containing microspheres loaded with bone morphogenetic proteins. J. Control. Release 2007, 121:81-90.
150. Gutwald R., Haberstroh J., Stricker A., Ruther E., Otto F., Xavier S.P., Oshima T., Marukawa E., Seto I., Enomoto S., Hoogendijk C.F., Schmelzeisen R., Sauerbier S. Influence of rhBMP-2 on bone formation and osseointegration in different implant systems after sinus-floor elevation. An in vivo study on sheep. J. Craniomaxillofac. Surg. 2010, 38:571-579.
151. Srouji S., Ben-David D., Lotan R., Livne E., Avrahami R., Zussman E. Slow-release human recombinant bone morphogenetic protein-2 embedded within electrospun scaffolds for regeneration of bone defect: in vitro and in vivo evaluation. Tissue Eng. Part A 2011, 17:269-277.
152. Ruhe P.Q., Kroese-Deutman H.C., Wolke J.G., Spauwen P.H., Jansen J.A. Bone inductive properties of rhBMP-2 loaded porous calcium phosphate cement implants in cranial defects in rabbits. Biomaterials 2004, 25:2123-2132.
153. Yan X.Z., Ge S.H., Sun Q.F., Guo H.M., Yang P.S. A pilot study evaluating the effect of recombinant human bone morphogenetic protein-2 and recombinant human beta-nerve growth factor on the healing of Class III furcation defects in dogs. J. Periodontol. 2010, 81:1289-1298.
154. Jiang X.Q., Sun X.J., Lai H.C., Zhao J., Wang S.Y., Zhang Z.Y. Maxillary sinus floor elevation using a tissue-engineered bone complex with beta-TCP and BMP-2 gene-modified bMSCs in rabbits. Clin. Oral Implants Res. 2009, 20:1333-1340.
155. Zhang Y., Fan W., Nothdurft L., Wu C., Zhou Y., Crawford R., Xiao Y. In vitro and in vivo evaluation of adenovirus combined silk fibroin scaffolds for bone morphogenetic protein-7 gene delivery. Tissue Eng. Part C Methods 2011, 17:789-797.
156. Hammarstrom L. Enamel matrix, cementum development and regeneration. J. Clin. Periodontol. 1997, 24:658-668.
157. Peng H., Usas A., Olshanski A., Ho A.M., Gearhart B., Cooper G.M., Huard J. VEGF improves, whereas sFlt1 inhibits, BMP2-induced bone formation and bone healing through modulation of angiogenesis. J. Bone Miner. Res. 2005, 20:2017-2027.
158. Wernike E., Montjovent M.O., Liu Y., Wismeijer D., Hunziker E.B., Siebenrock K.A., Hofstetter W., Klenke F.M. VEGF incorporated into calcium phosphate ceramics promotes vascularisation and bone formation in vivo. Eur. Cell. Mater. 2011, 19:30-40.
159. Young S., Patel Z.S., Kretlow J.D., Murphy M.B., Mountziaris P.M., Baggett L.S., Ueda H., Tabata Y., Jansen J.A., Wong M., Mikos A.G. Dose effect of dual delivery of vascular endothelial growth factor and bone morphogenetic protein-2 on bone regeneration in a rat critical-size defect model. Tissue Eng. Part A 2009, 15:2347-2362.
160. Patel Z.S., Young S., Tabata Y., Jansen J.A., Wong M.E., Mikos A.G. Dual delivery of an angiogenic and an osteogenic growth factor for bone regeneration in a critical size defect model. Bone 2008, 43:931-940.
161. Aghaloo T.L., Moy P.K., Freymiller E.G. Evaluation of platelet-rich plasma in combination with anorganic bovine bone in the rabbit cranium: a pilot study. Int. J. Oral Maxillofac. Implants 2004, 19:59-65.
162. Tonetti M.S., Cortellini P., Carnevale G., Cattabriga M., de Sanctis M., Pini Prato G.P. A controlled multicenter study of adjunctive use of tetracycline periodontal fibers in mandibular class II furcations with persistent bleeding. J. Clin. Periodontol. 1998, 25:728-736.
163. Mombelli A., Feloutzis A., Bragger U., Lang N.P. Treatment of peri-implantitis by local delivery of tetracycline. Clinical, microbiological and radiological results. Clin. Oral Implants Res. 2001, 12:287-294.
164. Rathbone C.R., Cross J.D., Brown K.V., Murray C.K., Wenke J.C. Effect of various concentrations of antibiotics on osteogenic cell viability and activity. J. Orthop. Res. 2011, 29:1070-1074.
165. Botelho M.A., Martins J.G., Ruela R.S., Queiroz D.B., Ruela W.S. Nanotechnology in ligature-induced periodontitis: protective effect of a doxycycline gel with nanoparticules. J. Appl. Oral Sci. 2010, 18:335-342.
166. Chang C.Y., Yamada S. Evaluation of the regenerative effect of a 25% doxycycline-loaded biodegradable membrane for guided tissue regeneration. J. Periodontol. 2000, 71:1086-1093.
167. Guelcher S.A., Brown K.V., Li B., Guda T., Lee B.H., Wenke J.C. Dual-purpose bone grafts improve healing and reduce infection. J. Orthop. Trauma 2011, 25:477-482.
168. Suzuki A., Terai H., Toyoda H., Namikawa T., Yokota Y., Tsunoda T., Takaoka K. A biodegradable delivery system for antibiotics and recombinant human bone morphogenetic protein-2: a potential treatment for infected bone defects. J. Orthop. Res. 2006, 24:327-332.
169. Yaffe A., Herman A., Bahar H., Binderman I. Combined local application of tetracycline and bisphosphonate reduces alveolar bone resorption in rats. J. Periodontol. 2003, 74:1038-1042.
170. Yaffe A., Golomb G., Breuer E., Binderman I. The effect of topical delivery of novel bisacylphosphonates in reducing alveolar bone loss in the rat model. J. Periodontol. 2000, 71:1607-1612.
171. Yaffe A., Iztkovich M., Earon Y., Alt I., Lilov R., Binderman I. Local delivery of an amino bisphosphonate prevents the resorptive phase of alveolar bone following mucoperiosteal flap surgery in rats. J. Periodontol. 1997, 68:884-889.
172. Binderman I., Adut M., Yaffe A. Effectiveness of local delivery of alendronate in reducing alveolar bone loss following periodontal surgery in rats. J. Periodontol. 2000, 71:1236-1240.
173. Srisubut S., Teerakapong A., Vattraphodes T., Taweechaisupapong S. Effect of local delivery of alendronate on bone formation in bioactive glass grafting in rats. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 2007, 104:e11-e16.
174. Wang C.Z., Chen S.M., Chen C.H., Wang C.K., Wang G.J., Chang J.K., Ho M.L. The effect of the local delivery of alendronate on human adipose-derived stem cell-based bone regeneration. Biomaterials 2010, 31:8674-8683.
175. Yaffe A., Binderman I., Breuer E., Pinto T., Golomb G. Disposition of alendronate following local delivery in a rat jaw. J. Periodontol. 1999, 70:893-895.
176. Bodde E.W., Kowalski R.S., Spauwen P.H., Jansen J.A. No increased bone formation around alendronate or omeprazole loaded bioactive bone cements in a femoral defect. Tissue Eng. Part A 2008, 14:29-39.
177. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws. J. Oral Maxillofac. Surg. 2007, 65:369-376.
178. King A.E., Umland E.M. Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates. Pharmacotherapy 2008, 28:667-677.
179. Miguel B.S., Ghayor C., Ehrbar M., Jung R.E., Zwahlen R.A., Hortschansky P., Schmoekel H.G., Weber F.E. N-methyl pyrrolidone as a potent bone morphogenetic protein enhancer for bone tissue regeneration. Tissue Eng. Part A 2009, 15:2955-2963.
180. Ozec I., Kilic E., Gumus C., Goze F. Effect of local simvastatin application on mandibular defects. J. Craniofac. Surg. 2007, 18:546-550.
181. Nyan M., Sato D., Oda M., Machida T., Kobayashi H., Nakamura T., Kasugai S. Bone formation with the combination of simvastatin and calcium sulfate in critical-sized rat calvarial defect. J. Pharmacol. Sci. 2007, 104:384-386.
182. Nyan M., Sato D., Kihara H., Machida T., Ohya K., Kasugai S. Effects of the combination with alpha-tricalcium phosphate and simvastatin on bone regeneration. Clin. Oral Implants Res. 2009, 20:280-287.